[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611630":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":48,"responsibleParty":74,"collaborators":77,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":42,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":42,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Mayo Hospital Lahore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rivaroxaban Group","ACTIVE_COMPARATOR","Arm 1 Title: Rivaroxaban Group Arm Type: Experimental Intervention Name: Drug: Rivaroxaban Descri",[13],"Drug: rivaroxaban (10mg)",{"label":15,"type":10,"description":16,"interventionNames":17},"Enoxaparin Group","Arm 2 Title: Enoxaparin Group\n\nArm Type: Active Comparator\n\nIntervention Name: Drug: Enoxaparin\n\nDescription: Participants receive enoxaparin 40 mg subcutaneously once daily for 7 days after emergency exploratory laparotomy, in addition to standard perioperative care and mechanical prophylaxis.",[18],"Drug: Enoxaparin 40 mg SC",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","rivaroxaban (10mg)","Name: Drug: Rivaroxaban\n\nType: Drug\n\nDescription: Participants receive rivaroxaban 10 mg orally once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.",[9],[26],"Xarelto",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Enoxaparin 40 mg SC","Name: Drug: Enoxaparin\n\nType: Drug\n\nDescription: Participants receive enoxaparin 40 mg subcutaneously once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.",[15],[32],"clexane",[34],{"name":35,"affiliation":5,"role":36},"Ahmad Uzair Qureshi, FCPS","STUDY_CHAIR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Muhammad Mashhood Shad, FCPS","CONTACT","+923040420285",null,"mashhood_shad@yahoo.com",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Shahroze Wajid, FCPS","+923054480616","mashhood0285@gmail.com",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Lahore","Punjab Province","54570","Pakistan","PK",{"type":57,"coordinates":58},"Point",[59,60],74.35071,31.558,{"lat":60,"lon":59},[63,67,71],{"name":64,"role":40,"phone":65,"phoneExt":42,"email":66},"Syed Asghar Naqi, FCPS","+924299211145","registrar@kemu.edu.pk",{"name":68,"role":40,"phone":69,"phoneExt":42,"email":70},"Zeeshan Sarwar, FCPS","+923228420433","mzeeshansarwar@gmail.com",{"name":72,"role":73,"phone":42,"phoneExt":42,"email":42},"Muhammad Mashhood Ahmad Shad, FCPS","PRINCIPAL_INVESTIGATOR",{"type":73,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Muhammad Mashhood Ahmad Shad","Principle Investigator",[78],{"name":79,"class":6},"King Edward Medical University","100611630","phase-4-comparative-efficacy-of-rivaroxaban-and-enoxaparin-in-post-laparotomy-dvt-prevention-100611630",false,"NCT07243080","Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","Comparison Between the Efficacy of Rivaroxaban vs Enoxaparin in Post-Operative Deep Venous Thrombosis Prophylaxis After Exploratory Laparotomy","Inclusion Criteria:• Patients aged 18 to 80 years\n\n* Both male or female patients\n* Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic\n* Patients with expected immobility for more than 24 hours\n\nExclusion Criteria:\n\n* Patients with diagnosed pre-operative DVT\n* BMI more than 40\n* Patient who are on mechanical ventilation post operatively\n* Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident\n* Patients who have undergone limb surgery in addition to exploratory laparotomy","ALL","18 Years","80 Years",{"count":91,"type":92},212,"ESTIMATED","INTERVENTIONAL",[95],"PHASE4","The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin.\n\nThe main questions it aims to answer are:\n\nDoes rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin?\n\nWhat medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin?\n\nResearchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery.\n\nParticipants will:\n\nTake rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery\n\nUndergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery\n\nBe monitored for bleeding, complications, and other side effects",[98,99],"Deep Venous Thromboses","Laparotomy Patients",[101,102,103,104,105,106,107,108,109],"Deep Vein Thrombosis","Exploratory Laparotomy","Rivaroxaban","Enoxaparin","Venous Thromboembolism","Anticoagulation","Prophylaxis","Randomized Controlled Trial","Thromboprophylaxis","2025-11-19",{"date":112,"type":113},"2025-11-21","ACTUAL",{"date":115,"type":113},"2025-10-10",{"date":117,"type":92},"2025-11-15",{"name":5,"class":6},1]